Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27997380 | 0.87 | RAF1 (0.40) | RAF1MAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL10068646 | 0.85 | ALDH1A1 (0.47) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL8928571 | 0.83 | MAPT (0.42) | RAF1MAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL12272543 | 0.81 | RAF1 (0.52) | RAF1MAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL12272546 | 0.81 | RAF1 (0.52) | RAF1MAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL12523234 | 0.80 | RAF1 (0.51) | RAF1MAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL12272822 | 0.78 | RAF1 (0.49) | RAF1MAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL1371646 | 0.77 | KMT2A (0.42) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL8928555 | 0.75 | MAPT (0.46) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL14419258 | 0.74 | GAA (0.44) | MAPTKMT2ATSHRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507228-B1 | NOVEL SPIROPIPERIDINE COMPOUNDS | LILLY CO ELI (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8822486-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2507228-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | Eli Lilly and Company (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120220616-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2011066183-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220616-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | REN, SLC5A1, SLC5A2 | RAF1 1234/4885MAPT 2499/4885KMT2A 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.